Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in:

16-05-2024 | Joint Infection | Brief Report

Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature

Authors: Barthelemy Lafon-Desmurs, Benoit Gachet, Benjamin Hennart, Benjamin Valentin, Gabrielle Roosen, Maxime Degrendel, Caroline Loiez, Eric Beltrand, Piervito D’Elia, Henri Migaud, Olivier Robineau, Eric Senneville

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2024

Login to get access

Abstract

Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2–7). Median time between two reinjections was 57 days (IQR 28–82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.
Appendix
Available only for authorised users
Literature
1.
Smeds MR, Duncan AA, Harlander-Locke MP, Lawrence PF, Lyden S, Fatima J et al (2016) Treatment and outcomes of aortic endograft infection. J Vasc Surg févr 63(2):332–340CrossRef
2.
3.
Zhang C, Liu Z, Lin Y, Cai Y, Zhang X, Huang Z et al (2022) Patient-reported outcome on quality of life and pain after revision arthroplasty for periprosthetic joint infection: A cross-sectional study. J Clin Med 11(23):7182CrossRefPubMedPubMedCentral
4.
Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis janv 56(1):e1-25CrossRef
5.
Pouderoux C, Becker A, Goutelle S, Lustig S, Triffault-Fillit C, Daoud F et al (2019) Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. J Antimicrob Chemother 74(7):2060–4CrossRefPubMed
6.
Rottier W, Seidelman J, Wouthuyzen-Bakker M (2023) Antimicrobial treatment of patients with a periprosthetic joint infection: basic principles. Arthroplasty 5(1):10CrossRefPubMedPubMedCentral
7.
Antonello RM, D’Oria M, Cavallaro M, Dore F, Cova MA, Ricciardi MC et al (2019) Management of abdominal aortic prosthetic graft and endograft infections. A multidisciplinary update. J Infect Chemother 25(9):669–80CrossRefPubMed
8.
9.
Escudero-Sanchez R, Senneville E, Digumber M, Soriano A, Del Toro MD, Bahamonde A et al (2020) Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect avr 26(4):499–505CrossRef
10.
Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH (2022) Clinical pharmacokinetics and pharmacodynamics of Dalbavancin. Clin Pharmacokinet 61(3):363–74CrossRefPubMed
11.
Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L et al (2019) Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection 47(6):1013–20CrossRefPubMed
12.
13.
Matt M, Duran C, Courjon J, Lotte R, Moing VL, Monnin B et al (2021) Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. J Glob Antimicrob Resist juin 25:341–345CrossRef
14.
Hitzenbichler F, Mohr A, Camboni D, Simon M, Salzberger B, Hanses F (2021) Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection févr 49(1):181–186CrossRef
15.
Gatti M, Viale P, Cojutti PG, Zamparini E, De Paolis M, Giannella M et al (2023) A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections. Int J Antimicrob Agents mai 61(5):106773CrossRef
16.
Cojutti PG, Rinaldi M, Gatti M, Tedeschi S, Viale P, Pea F (2021) Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. Int J Antimicrob Agents 58(5):106445CrossRefPubMed
17.
Simon S, Frank BJH, Hartmann S, Hinterhuber L, Reitsamer M, Aichmair A et al (2022) Dalbavancin in Gram-positive periprosthetic joint infections. J Antimicrob Chemother 77(8):2274–7CrossRefPubMed
18.
Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A et al (2019) French national cohort of first use of dalbavancin: A high proportion of off-label use. Int J Antimicrob Agents 54(5):668–72CrossRefPubMed
19.
Núñez-Núñez M, Casas-Hidalgo I, García-Fumero R, Vallejo-Rodríguez I, Anguita-Santos F, Hernández-Quero J et al (2020) Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm 27(5):310–312CrossRefPubMed
20.
Spaziante M, Franchi C, Taliani G, D’Avolio A, Pietropaolo V, Biliotti E et al (2019) Serum bactericidal activity levels monitor to guide Intravenous Dalbavancin Chronic suppressive therapy of inoperable staphylococcal prosthetic Valve Endocarditis: A case report. Open Forum Infect Dis 6(11):ofz427CrossRefPubMedPubMedCentral
21.
Howard-Anderson J, Pouch SM, Sexton ME, Mehta AK, Smith AL, Lyon GM et al (2019) Left ventricular assist device infections and the potential role for Dalbavancin: A case report. Open Forum Infect Dis 6(9):ofz235CrossRefPubMedPubMedCentral
22.
Barbero Allende JM, García Sánchez M, CulebrasLópez AM, Agudo AR (2021) Suppressive antibiotic treatment with dalbavancin. A case report. Rev Esp Quimioter 34(2):151–3CrossRefPubMed
23.
Matesanz M, Poza A, Iñurrieta A, Fernández-Diaz E, Arroyo M, Domínguez I et al (2021) Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus. Rev Esp Quimioter août 34(4):396–399CrossRef
24.
Ruiz-Sancho A, Núñez-Núñez M, Castelo-Corral L, Martínez-Marcos FJ, Lois-Martínez N, Abdul-Aziz MH et al (2023) Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety. Front Pharmacol 14:1185602CrossRefPubMedPubMedCentral
25.
Lepak A, Marchillo K, VanHecker J, Andes D (2015) Impact of glycopeptide resistance in staphylococcus aureus on the Dalbavancin In Vivo pharmacodynamic target. Antimicrob Agents Chemother déc 59(12):7833–7836CrossRef
26.
Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Pérez S, López-Medrano F, San Juan-Garrido R, Ferrari-Piquero JM (2022) Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm janv 29(1):55–58CrossRef
27.
Zhang R, Polenakovik H, Barreras Beltran IA, Waalkes A, Salipante SJ, Xu L et al (2022) Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a patient treated with Dalbavancin: Case report and isolate characterization. Clin Infect Dis 75(9):1641–4CrossRefPubMedPubMedCentral
28.
Werth BJ, Jain R, Hahn A, Cummings L, Weaver T, Waalkes A et al (2018) Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect avr 24(4):429.e1-429.e5CrossRef
29.
Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D et al (2018) Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect 7:202CrossRefPubMedPubMedCentral
Metadata
Title
Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature
Authors
Barthelemy Lafon-Desmurs
Benoit Gachet
Benjamin Hennart
Benjamin Valentin
Gabrielle Roosen
Maxime Degrendel
Caroline Loiez
Eric Beltrand
Piervito D’Elia
Henri Migaud
Olivier Robineau
Eric Senneville
Publication date
16-05-2024
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2024
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-024-04849-0

Other articles of this Issue 7/2024

European Journal of Clinical Microbiology & Infectious Diseases 7/2024 Go to the issue

Original Article

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021

Research

Rapid colorimetric polymyxin B microelution directly from positive blood bottles: because patients with serious infections should not have to wait for results of culture-based methodologies

Research

Epidemiology and antimicrobial resistance patterns of bacterial meningitis among hospitalized patients at a tertiary care hospital in Saudi Arabia: a six-year retrospective study

Original Article

Antimicrobial susceptibility testing reveals reduced susceptibility to azithromycin and other antibiotics in Legionella pneumophila serogroup 1 isolates from Portugal

Brief Report

The role of time to positive blood cultures in enhancing the predictive capability of DENOVA score for diagnosing infective endocarditis in patients with Enterococcus faecalis bacteremia

Brief Report

Non-cholera Vibrio spp. invasive infections in the summer following May 2023 flood disaster in Romagna, Italy: a case series

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits